sodium colistimethate g.e.s süste-/infusioonilahuse pulber
altan pharmaceuticals s.a - kolistiin - süste-/infusioonilahuse pulber - 1000000tÜ 10tk
colistimethate sodium auxilia süste-/infusioonilahuse pulber
auxilia pharma oÜ - kolistiin - süste-/infusioonilahuse pulber - 1000000rÜ 10tk
controloc 40 mg gastroresistentne tablett
takeda gmbh - pantoprasool - gastroresistentne tablett - 40mg 28tk; 40mg 10tk; 40mg 7tk; 40mg 112tk; 40mg 50tk; 40mg 84tk; 40mg 500tk; 40mg 60tk; 40mg 48tk; 40mg 49tk; 40mg 56tk; 40mg 700tk; 40mg 15tk; 40mg 14tk
alfacalcidol strides pharma pehmekapsel
strides pharma (cyprus) limited - alfakaltsidool - pehmekapsel - 1mcg 30tk; 1mcg 50tk; 1mcg 100tk; 1mcg 90tk
alfacalcidol strides pharma pehmekapsel
strides pharma (cyprus) limited - alfakaltsidool - pehmekapsel - 0,25mcg 100tk; 0,25mcg 50tk; 0,25mcg 90tk
alfacalcidol strides pharma pehmekapsel
strides pharma (cyprus) limited - alfakaltsidool - pehmekapsel - 0,5mcg 30tk; 0,5mcg 100tk; 0,5mcg 50tk; 0,5mcg 90tk
alfacalcidol sandoz pehmekapsel
sandoz pharmaceuticals d.d. - alfakaltsidool - pehmekapsel - 1mcg 20tk; 1mcg 60tk; 1mcg 30tk; 1mcg 100tk; 1mcg 50tk
alfacalcidol sandoz pehmekapsel
sandoz pharmaceuticals d.d. - alfakaltsidool - pehmekapsel - 0,5mcg 20tk; 0,5mcg 100tk; 0,5mcg 30tk; 0,5mcg 60tk
alfacalcidol sandoz pehmekapsel
sandoz pharmaceuticals d.d. - alfakaltsidool - pehmekapsel - 0,25mcg 20tk; 0,25mcg 30tk; 0,25mcg 90tk; 0,25mcg 50tk; 0,25mcg 100tk
epoetin alfa hexal
hexal ag - alfa-epoetiin - anemia; kidney failure, chronic; cancer - antianemilised preparaadid - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. ravi aneemia ja vähendada vereülekande nõuete täiskasvanud patsientidest, keemiaravi tahkete kasvajate, pahaloomulise lümfoomi või hulgimüeloom, ja on oht, vereülekande kui hinnata patsiendi üldist seisundit (e. südame-veresoonkonna seisund, pre-olemasolevate aneemia alguses keemiaravi).